Physician profile
Saba Shabnam
NPI 1225091655
$870.12
in general payments reported to CMS, 2019-2025
15 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $195 · 2021: $36.60 · 2022: $91.80 · 2023: $38.13 · 2024: $39.21 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $247.90 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $110.76 | 2019 | |
| Amgen INC. | $88.26 | 2020-2025 | Otezla, Repatha |
| Novo Nordisk INC | $80.75 | 2019-2020 | |
| Shield Therapeutics INC | $79.10 | 2022-2024 | Accrufer |
| Lilly USA, LLC | $49.94 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Ibsa Pharma INC. | $42.23 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.87 | 2019-2022 | |
| Astellas Pharma US INC | $24.92 | 2025 | Veozah |
| Mannkind Corporation | $19.98 | 2019 | |
| Abbott Laboratories | $19.93 | 2019 | |
| Esperion Therapeutics, INC. | $19.07 | 2024 | Nexletol |
| Vivus LLC | $17.25 | 2020 | |
| Phadia US INC. | $16.66 | 2021 | |
| Antares Pharma, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saba Shabnam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.